Journal of Heart and Lung Transplantation最新文献

筛选
英文 中文
Tacrolimus, cyclosporine, and lung transplantation in the "real world". 他克莫司、环孢素和肺移植的 "真实世界"。
IF 6.4 1区 医学
Journal of Heart and Lung Transplantation Pub Date : 2024-11-23 DOI: 10.1016/j.healun.2024.11.023
Kieran Halloran
{"title":"Tacrolimus, cyclosporine, and lung transplantation in the \"real world\".","authors":"Kieran Halloran","doi":"10.1016/j.healun.2024.11.023","DOIUrl":"10.1016/j.healun.2024.11.023","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell RNA-sequencing identifies unique cell-specific gene expression profiles in high-grade cardiac allograft vasculopathy. 单细胞 RNA 测序确定了高级别心脏异体移植血管病变中独特的细胞特异性基因表达谱。
IF 6.4 1区 医学
Journal of Heart and Lung Transplantation Pub Date : 2024-11-22 DOI: 10.1016/j.healun.2024.11.017
Kaushik Amancherla, Kelly H Schlendorf, Nelson Chow, Quanhu Sheng, Jane E Freedman, Jeffrey C Rathmell
{"title":"Single-cell RNA-sequencing identifies unique cell-specific gene expression profiles in high-grade cardiac allograft vasculopathy.","authors":"Kaushik Amancherla, Kelly H Schlendorf, Nelson Chow, Quanhu Sheng, Jane E Freedman, Jeffrey C Rathmell","doi":"10.1016/j.healun.2024.11.017","DOIUrl":"10.1016/j.healun.2024.11.017","url":null,"abstract":"<p><strong>Background: </strong>Cardiac allograft vasculopathy (CAV) is the leading cause of late graft failure and mortality after heart transplantation (HT). Current strategies for early diagnosis and effective treatment of CAV are lacking. Using single-cell RNA-sequencing in peripheral blood mononuclear cells (PBMCs), we sought to investigate cell-specific gene expression profiles and T cell receptor repertoires in CAV that may inform novel biomarkers and pathways to interrupt CAV pathogenesis.</p><p><strong>Methods: </strong>Whole blood was collected from 22 HT recipients with angiographically-confirmed CAV and 18 HT recipients without CAV. PBMCs were isolated and subjected to single-cell RNA-sequencing using a 10X Genomics microfluidic platform. Downstream analyses focused on differential expression of genes, cell compositional changes, and T cell receptor repertoire analyses.</p><p><strong>Results: </strong>Across 40 PBMC samples, we isolated 134,984 cells spanning 31 cell types. Compositional analyses showed subtle, but significant increases in CD4+ T central memory cells, and CD14+ and CD16+ monocytes in high-grade CAV (CAV-2 and CAV-3). 745 genes were differentially expressed in a cell-specific manner in high-grade CAV, enriched for putative pathways involved in inflammation and angiogenesis. Intersection with the druggable genome prioritized 68 targets, including targets with approved drugs in cardiovascular disease (e.g., canakinumab). There were no significant differences in T cell clonality or diversity with increasing CAV severity.</p><p><strong>Conclusions: </strong>Unbiased whole transcriptomic analyses at single-cell resolution identify unique, cell-specific gene expression patterns in CAV, suggesting the potential utility of peripheral gene expression biomarkers in diagnosing CAV. Furthermore, precision targeting of these pathways may offer opportunities to mitigate CAV pathogenesis.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanical circulatory support and post-transplant infections: Is temporary MCS really riskier? 机械循环支持与移植后感染:临时性机械循环支持真的更危险吗?
IF 6.4 1区 医学
Journal of Heart and Lung Transplantation Pub Date : 2024-11-20 DOI: 10.1016/j.healun.2024.11.010
Saima Aslam
{"title":"Mechanical circulatory support and post-transplant infections: Is temporary MCS really riskier?","authors":"Saima Aslam","doi":"10.1016/j.healun.2024.11.010","DOIUrl":"10.1016/j.healun.2024.11.010","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extended duration of ex-vivo perfusion is associated with worse survival in donation after circulatory death heart recipients: A national database analysis. 延长体外灌注时间与循环死亡后捐献心脏受者存活率下降有关:全国数据库分析
IF 6.4 1区 医学
Journal of Heart and Lung Transplantation Pub Date : 2024-11-20 DOI: 10.1016/j.healun.2024.11.018
Ruby Singh, George Olverson, Kristian Punu, Adham Makarem, Chijioke C Chukwudi, Sarah A Brownlee, Antonia Kreso, Seyed Alireza Rabi, Eriberto Michel, Gregory D Lewis, David A D'Alessandro, Asishana A Osho
{"title":"Extended duration of ex-vivo perfusion is associated with worse survival in donation after circulatory death heart recipients: A national database analysis.","authors":"Ruby Singh, George Olverson, Kristian Punu, Adham Makarem, Chijioke C Chukwudi, Sarah A Brownlee, Antonia Kreso, Seyed Alireza Rabi, Eriberto Michel, Gregory D Lewis, David A D'Alessandro, Asishana A Osho","doi":"10.1016/j.healun.2024.11.018","DOIUrl":"10.1016/j.healun.2024.11.018","url":null,"abstract":"<p><strong>Background: </strong>The impact of duration of ex-vivo heart perfusion (EVHP) on patient outcomes following donation after circulatory death (DCD) heart transplantation has not been established.</p><p><strong>Methods: </strong>Adult first-time DCD heart transplants using EVHP were identified in the Organ Procurement & Transplant Network database (12/2019-09/2023). Total out of body time (OBT) was dichotomized based on perfusion duration exceeding the 90th percentile of EVHP hearts in the study. The primary outcome of 6-month mortality was assessed using Kaplan Meier curves and multivariable Cox regression. 30-day, 1-year, and 3-year mortality were also assessed. Secondary postoperative outcomes of index hospitalization length of stay, acute rejection, dialysis, and stroke were assessed using univariable linear or logistic regression.</p><p><strong>Results: </strong>Among 575 recipients of DCD transplantations using EVHP, 58 hearts had extended perfusion times based on an OBT cutoff of 8.3 hours which identified OBT greater than the 90th percentile. Extended perfusion heart recipients had worse overall mortality at 6 months compared to standard perfusion hearts after adjusting for critical donor and recipient factors [aHR = 2.48(1.25,4.93),p = 0.009]. Early 30-day mortality was comparable between the groups (p = 0.592). However, 1-year and 3-year outcomes showed worse mortality in recipients of extended perfusion hearts (both p < 0.05). Post-transplant dialysis requirement and increased length of stay was more likely in the extended perfusion group (both p < 0.05). There was no difference in acute rejection (p = 0.163), and stroke (p = 0.170).</p><p><strong>Conclusions: </strong>There is a potential detrimental effect of extended EVHP duration on DCD heart recipient survival. Future work will explore the identified opportunity to improve organ preservation during EVHP.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nr4a1: A multilevel target to overcome PGD in lung transplantation. Nr4a1:克服肺移植中 PGD 的多层次靶点。
IF 6.4 1区 医学
Journal of Heart and Lung Transplantation Pub Date : 2024-11-20 DOI: 10.1016/j.healun.2024.11.008
Cedric Vanluyten, Robin Vos, Laurens J Ceulemans
{"title":"Nr4a1: A multilevel target to overcome PGD in lung transplantation.","authors":"Cedric Vanluyten, Robin Vos, Laurens J Ceulemans","doi":"10.1016/j.healun.2024.11.008","DOIUrl":"10.1016/j.healun.2024.11.008","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Donor-derived cell-free DNA as a new biomarker for cardiac allograft rejection: A prospective study (FreeDNA-CAR). 作为心脏异体移植排斥反应新生物标志物的供体源性细胞游离 DNA:一项前瞻性研究(FreeDNA-CAR)。
IF 6.4 1区 医学
Journal of Heart and Lung Transplantation Pub Date : 2024-11-20 DOI: 10.1016/j.healun.2024.11.009
Marta Jiménez-Blanco, Maria Generosa Crespo-Leiro, Maria Dolores García-Cosío Carmena, Manuel Gómez Bueno, Raquel López-Vilella, Carlos Ortiz-Bautista, Marta Farrero-Torres, Isabel Zegrí-Reiriz, Beatriz Díaz-Molina, Elena García-Romero, Diego Rangel-Sousa, Nahikari Salterain, Iris Garrido Bravo, Javier Segovia-Cubero
{"title":"Donor-derived cell-free DNA as a new biomarker for cardiac allograft rejection: A prospective study (FreeDNA-CAR).","authors":"Marta Jiménez-Blanco, Maria Generosa Crespo-Leiro, Maria Dolores García-Cosío Carmena, Manuel Gómez Bueno, Raquel López-Vilella, Carlos Ortiz-Bautista, Marta Farrero-Torres, Isabel Zegrí-Reiriz, Beatriz Díaz-Molina, Elena García-Romero, Diego Rangel-Sousa, Nahikari Salterain, Iris Garrido Bravo, Javier Segovia-Cubero","doi":"10.1016/j.healun.2024.11.009","DOIUrl":"10.1016/j.healun.2024.11.009","url":null,"abstract":"<p><strong>Background: </strong>There is a long-standing need for a noninvasive biomarker that allows monitoring of cardiac allograft rejection, avoiding the need for periodic endomyocardial biopsies (EMB).</p><p><strong>Methods: </strong>Multicenter, observational, prospective study, performed between 2019 and 2023 (NCT04973943). All patients underwent 7 per-protocol surveillance EMB during the first postheart transplantation year. Donor-derived cell-free DNA (dd-cfDNA) levels were determined before each EMB, using Next Generation Sequencing Technology (Allonext assay, Eurofins Genome). The primary end-point was the association between dd-cfDNA levels and the presence of acute cellular rejection (ACR) in EMB.</p><p><strong>Results: </strong>The study included 206 patients from 12 centers, with 1,090 pairs of EMB/dd-cfDNA determinations available for analysis. EMB with ACR (n = 49) were associated with dd-cfDNA levels significantly higher than those without, median 0.189% (interquartilic range 0.05-0.70) vs 0.095% (0.04-0.23), p = 0.013. A dd-cfDNA threshold of 0.10% showed a negative predictive value for ACR of 97%. A statistically significant association between N-terminal prohormone of brain (NTProBNP) and dd-cfDNA was also found, with an increase of 0.007% dd-cfDNA (95% confidence interval 0.003-0.011) for every 500 units of NTproBNP, p 0.001. The combination of both biomarkers for diagnosis of ACR showed an area under the receiver operating characteristic (ROC) curve of 0.681, and this combined approach was significantly better than dd-cfDNA alone (area under the ROC curve 0.603), p = 0.016. Using a cut-off point of 0.10% for dd-cfDNA and 1,000 UI/ml for NTproBNP, negative predictive value increased to 98.1%.</p><p><strong>Conclusions: </strong>dd-cfDNA may be a useful biomarker to rule out significant ACR in a low-risk population. However, a dd-cfDNA value above normal threshold does not correlate robustly with the presence of disease. The combination with NTproBNP, a readily available biomarker, increased the discrimination power of dd-cfDNA alone.</p><p><strong>Clinical trial notation: </strong>Donor-derived Cell-Free DNA as a New Biomarker in Cardiac Acute Rejection, NCT04973943.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Tale of Two Indications for EVLP. EVLP 两种适应症的故事。
IF 6.4 1区 医学
Journal of Heart and Lung Transplantation Pub Date : 2024-11-19 DOI: 10.1016/j.healun.2024.11.022
Kenneth R McCurry, Toshihiro Okamoto
{"title":"A Tale of Two Indications for EVLP.","authors":"Kenneth R McCurry, Toshihiro Okamoto","doi":"10.1016/j.healun.2024.11.022","DOIUrl":"https://doi.org/10.1016/j.healun.2024.11.022","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of agonal phase duration with heart utilization and post-transplant outcomes in donation after circulatory death heart transplantation. 在循环死亡后捐献的心脏移植手术中,激动期持续时间与心脏利用率和移植后结果的关系。
IF 6.4 1区 医学
Journal of Heart and Lung Transplantation Pub Date : 2024-11-19 DOI: 10.1016/j.healun.2024.11.011
Yeahwa Hong, Nicholas R Hess, Ander Dorken-Gallastegi, Nidhi Iyanna, Gavin W Hickey, Michael A Mathier, Dennis M McNamara, Mary E Keebler, Edward T Horn, David J Kaczorowski
{"title":"Association of agonal phase duration with heart utilization and post-transplant outcomes in donation after circulatory death heart transplantation.","authors":"Yeahwa Hong, Nicholas R Hess, Ander Dorken-Gallastegi, Nidhi Iyanna, Gavin W Hickey, Michael A Mathier, Dennis M McNamara, Mary E Keebler, Edward T Horn, David J Kaczorowski","doi":"10.1016/j.healun.2024.11.011","DOIUrl":"10.1016/j.healun.2024.11.011","url":null,"abstract":"<p><strong>Background: </strong>This study evaluates the impact of the agonal phase and related hemodynamic measures on post-transplant outcomes and heart utilization in donation after circulatory death (DCD) heart transplantation.</p><p><strong>Methods: </strong>United Network for Organ Sharing registry was queried to analyze adult recipients who underwent isolated DCD heart transplantation between January 1, 2019 and September 30, 2023. The recipients were stratified into 2 groups based on donor agonal period: <30 and ≥30 minutes. The primary outcome was 90-day post-transplant survival. Propensity score-matching was performed. Sub-analysis was performed to evaluate the association of agonal period with donor heart utilization. Additionally, the associations between different hemodynamic thresholds used to indicate onset of warm ischemia during the agonal phase with 90-day mortality were compared.</p><p><strong>Results: </strong>Eight hundred and eighty nine recipients were included, with 179 (20.1%) receiving hearts from donors with an agonal period of ≥30 minutes. Ninety-day survival (88.1% vs. 95.6%, p < 0.001) was significantly lower among the recipients of donors with an agonal period of ≥30 minutes. The lower 90-day survival persisted in a propensity score-matched comparison. Furthermore, longer agonal periods were associated with reduced donor heart utilization. Lastly, a time interval from a systolic blood pressure of 80 ± 5mmHg to death exhibited significantly higher association with 90-day mortality than a time interval from a systemic oxygen saturation 80 ± 5% to death.</p><p><strong>Conclusions: </strong>Utilizing DCD donor hearts with agonal periods ≥30 minutes is associated with reduced post-transplant survival and decreased donor heart utilization. When assessing the onset of warm ischemia during the agonal phase, hypotension may serve as a more accurate indicator of myocardial ischemia and provide improved post-transplant prognostic insight than hypoxia.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promise of a new day - will EVLP fulfill its therapeutic potential? 新一天的希望--EVLP能否实现其治疗潜力?
IF 6.4 1区 医学
Journal of Heart and Lung Transplantation Pub Date : 2024-11-19 DOI: 10.1016/j.healun.2024.11.019
Srineil Vuthaluru, Aleem Siddique
{"title":"Promise of a new day - will EVLP fulfill its therapeutic potential?","authors":"Srineil Vuthaluru, Aleem Siddique","doi":"10.1016/j.healun.2024.11.019","DOIUrl":"10.1016/j.healun.2024.11.019","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Donor sequence number is not associated with worse lung transplant outcomes regardless of transplant center case volume. 无论移植中心的病例量如何,供体序列号与较差的肺移植结果无关。
IF 6.4 1区 医学
Journal of Heart and Lung Transplantation Pub Date : 2024-11-19 DOI: 10.1016/j.healun.2024.11.012
Alfred J Casillan, Emily L Larson, Alice L Zhou, Jessica M Ruck, Armaan F Akbar, Allan B Massie, Dorry L Segev, Christian A Merlo, Errol L Bush
{"title":"Donor sequence number is not associated with worse lung transplant outcomes regardless of transplant center case volume.","authors":"Alfred J Casillan, Emily L Larson, Alice L Zhou, Jessica M Ruck, Armaan F Akbar, Allan B Massie, Dorry L Segev, Christian A Merlo, Errol L Bush","doi":"10.1016/j.healun.2024.11.012","DOIUrl":"10.1016/j.healun.2024.11.012","url":null,"abstract":"<p><strong>Background: </strong>Potential lung transplantation (LTx) recipients are assigned a donor sequence number (DSN) based on their position on the match list. Since a higher DSN offer has already been declined for other recipients, some providers may assume that a high DSN connotates poorer allograft quality. This study evaluated the association between DSN and outcomes, the correlation between transplant program case volume and the utilization of higher DSN lungs, and whether LTx outcomes differ between lower- and higher-volume programs.</p><p><strong>Methods: </strong>Using the Scientific Registry of Transplant Recipients database, LTx cases from 2015-2021 were retrospectively reviewed. Recipients were categorized into low (<20), medium (21-50), high (51-100), and very high (>100) DSN groups. The primary outcome was LTx survival. For cases involving high or very high DSN donors, a subgroup analysis compared survival among programs with annual transplant volumes in the bottom, middle 2, and top quartiles.</p><p><strong>Results: </strong>Median survival was similar among the low (6.9 years), medium (6.1), high (5.9), and very high DSN (6.5) groups (log-rank p = 0.09). Higher DSN donors were more commonly accepted by higher-volume LTx centers. However, the annual case volume of the transplanting institution did not impact survival when high (log-rank p = 0.16) or very high DSN (log-rank p = 0.36) donors were used.</p><p><strong>Conclusions: </strong>Higher DSN should not be considered an independent marker of low allograft quality. Additionally, lower-volume centers achieved similar post-transplant outcomes as higher-volume centers for recipients receiving higher DSN lungs. These findings underscore that surgeons must judge each donor offer independent of other programs' assessments.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信